ANGO News Alert Angiodynamics (ANGO) 18.78 02/13/2015 22:22:

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 11:22 PM

Angiodynamics (ANGO) 18.78 $ANGO

Shares of ANGO Up 19.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 10:00AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 19.20% as of today's recent price of $18.16.
ANGO: 18.78 (+0.18)

Uptrend Call Working As Angiodynamics Stock Rises 21.8% (ANGO)
Comtex SmarTrend(R) - Wed Feb 04, 9:24AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 4 months, Angiodynamics has returned 21.82% as of today's recent price of $18.56.
ANGO: 18.78 (+0.18)

AngioDynamics Celerity System Gets Expanded FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:00PM CST
Per the latest approval, clinicians can do away with the follow-up X-ray when AngioDynamics Inc.'s (ANGO) Celerity system is used to assist in the positioning of PICCs in adult patients.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ANGO: 18.78 (+0.18), SURG: 4.44 (-0.02)

AngioDynamics Receives Expanded "No Chest X-Ray" FDA Clearance for Celerity Tip Location System
GlobeNewswire - Thu Jan 29, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for the Celerity tip location system.
ANGO: 18.78 (+0.18)

22.0% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Tue Jan 20, 11:15AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 3 months, Angiodynamics has returned 22.02% as of today's recent price of $18.59.
ANGO: 18.78 (+0.18)

AngioDynamics Still Looking For Inflection
Stephen Simpson, CFA - at Seeking Alpha - Sat Jan 10, 11:59AM CST

BCR: 175.38 (+0.50), TFX: 112.07 (+0.47), ANGO: 18.78 (+0.18)

AngioDynamics Beats Q2 Earnings by a Penny, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:10AM CST
AngioDynamics Inc. (ANGO) reported second-quarter 2015 earnings of 17 cents per share, which beat the Zacks Consensus Estimate by a penny
BSX: 14.98 (+0.24), BCR: 175.38 (+0.50), ANGO: 18.78 (+0.18), MMSI: 17.27 (-0.16)

AngioDynamics reports FQ2, ups earnings guidance
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 6:09AM CST

ANGO: 18.78 (+0.18)

uniQure Appoints Matthew Kapusta as Chief Financial Officer
GlobeNewswire - Fri Jan 09, 4:08AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Company nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. In addition, uniQure announced the following changes to its Supervisory Board: Francois Meyer, a member of the Supervisory Boards of uniQure and its predecessor company AMT since 2010, and Sander Slootweg, Managing Partner of Forbion Capital Partners and Supervisory Board Member from 2006 to 2008 and again starting in 2012, will step down from the Supervisory Board. Philip Astley-Sparke, who has overseen uniQure's U.S. operations over the past two years, will be nominated for appointment to the Supervisory Board and will pass his operational responsibilities to Mr. Kapusta, who will be based in uniQure's Massachusetts manufacturing facility. Additionally, Prof. Hugo Katus, who is recognized as one of the leading heart surgeons and clinicians worldwide, has agreed to be nominated for appointment to the Supervisory Board. These changes are intended to add relevant breadth of experience and independence to the uniQure Supervisory Board.
QURE: 19.83 (-0.18), ANGO: 18.78 (+0.18)

AngioDynamics' (ANGO) CEO Joe DeVivo on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 08, 10:28PM CST

ANGO: 18.78 (+0.18)

AngioDynamics (ANGO) Stock Climbs in After-Hours Trading Today Following Earnings Beat
at The Street - Thu Jan 08, 3:43PM CST
AngioDynamics (ANGO) shares are rising after the company beat analysts' second quarter earnings and revenue expectations.
ANGO: 18.78 (+0.18)

AngioDynamics (ANGO) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 08, 3:25PM CST

ANGO: 18.78 (+0.18)

AngioDynamics Reports 2015 Second Quarter Financial Results
GlobeNewswire - Thu Jan 08, 3:06PM CST
-- Second Quarter Fiscal 2015 Net Sales increased 4% to $92.1 million; 5% sales growth excluding supply agreement
ANGO: 18.78 (+0.18)

AngioDynamics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:04PM CST

ANGO: 18.78 (+0.18)

Natus Medical Advances Newborn Care with Nicview Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:42PM CST
Natus Medical Inc (BABY) is presently focusing on enhancing its offerings for the newborn care market
JNJ: 99.62 (+1.18), ABMD: 60.39 (+0.46), BABY: 36.96 (-0.03), ANGO: 18.78 (+0.18)

IDEXX CAG, Global Growth Solid; Catalyst One in Focus in '15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 12:20PM CST
On Jan 7, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
HNSN: 1.05 (+0.02), EW: 134.23 (+1.89), IDXX: 159.08 (+1.72), ANGO: 18.78 (+0.18)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST

HELE: 77.94 (-0.34), RT: 6.40 (+0.20), BBBY: 77.91 (-0.49), VOXX: 8.85 (+0.10), PSMT: 84.79 (+0.39), EOPN: 8.55 (-0.01), CUDA: 35.68 (-1.14), TCS: 20.17 (+0.15), ANGO: 18.78 (+0.18)

Globus Medical Announces Preliminary Q4 & 2014 Sales Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 4:35PM CST
Musculoskeletal implant manufacturer, Globus Medical Inc. (GMED) recently announced preliminary sales result for the fourth quarter and full-year 2014
ABMD: 60.39 (+0.46), GMED: 24.85 (+0.45), ANGO: 18.78 (+0.18), SURG: 4.44 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

National Showrooms Expands into Virginia with Key Buy

A New Chapter for Greenwich Kitchens I'll tell you what's catching my eye this time—National Kitchen & Bath Showrooms are making their move into Virginia by snapping up Greenwich Kitchens, a well-regarded name in the local kitchen and bath scene. Founded back in '78, Greenwich Kitchens has been a staple in the Virginia Beach and Hampton Roads areas for nearly half a...

OppFi Readies Q3 Earnings; Investors Eye Financials

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

Plata Hits $1 Billion ARR in Record Digital Bank Growth

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

INSPIRE 2026: Luxury Hotel Trends and Investments

Luxury Hotels: Where's the Money Headed? All eyes on Orlando this December 15–16, where the International Luxury Hotel Association (ILHA) is calling the shots. INSPIRE 2026 is the marquee event of the year for luxury hospitality, and it ain't just about starry chandeliers and velvet drapes. We're talking real capital shifts, margins pinching tighter, and a future...

Security Leadership Faces Unseen Identity Risks

Rocky Road in Identity Security Catch this: you're a security honcho, thinking you've forked over enough dough to lock down human and machine identities. But now, it turns out, most of your kind still don't have a full handle on who or what is poking around your systems. Talk about a wrench in the gears. This latest report from Oak drags the reality into the limelight:...

Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Art Print Paper: Finding the Perfect Match for Masterpieces

You ever stand in a gallery and notice how some art just lights up the room while others barely get a second glance? Well, a lot of that magic starts with an unsung hero—paper choice. I came across this bit from HelloNation diving into what makes paper selection a cornerstone for fine art prints. Now, I ain't an artist, but even a bruiser trader like me can see the...

Tumor Ablation Market: Charting a Billion-Dollar Surge

Cancer's Unforgiving Climb: Opportunity Amidst Challenge Looking at the current state of the global tumor ablation market, one thing's clear—it's on a sort of upward swing you'd expect trains to make, riding the rails of rising cancer rates and technological advancements. At least that's what the folks at Wissen Research are banking on, projecting a leap to $1.8 billion...

Meitav Tops 2025 Service Index with Stellar Growth

Meitav’s Leap to The Summit Damn, it's a wild market when a pension fund provider snatches the crown. But here we are, looking at Meitav Provident Funds and Pension Ltd., standing proudly as Israel's top dog in the 2025 Service Index for pension funds. We're talking a jump from fourth to numero uno, folks, with a hefty score of 83 out of 100. And don't sleep on their...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...